Health Library · Eligibility & Decision Making
Who Is a Candidate for CAR-T Cell Therapy?
Educational guide · Updated 2026
CAR-T cell therapy is a powerful option for certain blood cancers, but it is not suitable for every patient. Eligibility depends on the type of disease, how many treatments have already been tried, the patient’s overall medical fitness, and practical factors related to cell collection and manufacturing.
This article explains the typical criteria used for the most established CAR-T indications (especially relapsed or refractory large B-cell lymphoma and related B-cell malignancies). Exact rules vary by product and by the treating center’s protocol, so the final decision is always individualized.
1. Disease type and status
Most currently approved or widely studied CAR-T products that target CD19 are intended for patients with:
- Relapsed or refractory large B-cell lymphoma (including diffuse large B-cell lymphoma and related entities)
- Certain other aggressive B-cell lymphomas after previous therapy
- In some programs, relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), especially in younger patients or specific age groups
“Relapsed” means the disease returned after a response. “Refractory” means the disease did not respond adequately to prior treatment. CAR-T is usually considered after at least two prior lines of therapy for large B-cell lymphoma, although the exact number of prior lines can depend on the product label and clinical situation.
Newer investigations are exploring CAR-T in other settings (including some autoimmune diseases), but these remain more specialized or earlier in development and are not the standard pathway for most patients today.
2. Prior treatments
A typical candidate has already received standard therapies such as:
- Chemo-immunotherapy (for example R-CHOP or similar regimens)
- Additional lines of chemotherapy or targeted agents
- In many cases, an autologous stem cell transplant has either been tried, was not possible, or the disease relapsed after transplant
The treating team reviews the full treatment history to confirm that conventional options have been reasonably exhausted or are no longer appropriate, and that CAR-T still offers a meaningful chance of benefit.
3. Medical fitness and organ function
Because CAR-T can cause significant side effects (including cytokine release syndrome, neurologic events, low blood counts and infections), patients need sufficient physiologic reserve. Centers generally assess:
- Performance status – ability to carry out daily activities (often measured by ECOG or similar scales)
- Heart function – adequate cardiac output and no uncontrolled heart failure
- Lung function – ability to tolerate potential respiratory stress
- Kidney and liver function – within acceptable ranges for the planned lymphodepleting chemotherapy and supportive care
- Blood counts and bone marrow reserve
- Absence of uncontrolled active infection
Age itself is not an absolute barrier. Older patients can be candidates if their overall fitness is good. Conversely, a younger patient with severe organ damage or very poor performance status may not be eligible.
4. Ability to collect and manufacture cells
CAR-T products that are autologous (made from the patient’s own cells) require successful collection of T cells through leukapheresis and successful manufacturing. Factors that can complicate this step include:
- Very low lymphocyte counts
- Recent treatments that strongly suppress T cells
- Certain infections or logistical barriers to collection
The manufacturing laboratory and clinical team evaluate whether an adequate starting material can be obtained and whether the cells are likely to expand properly.
5. Disease control while waiting for the product
Manufacturing takes time (often measured in weeks). During this “vein-to-vein” period the disease must remain manageable. Some patients need bridging therapy (additional treatment given after cell collection but before CAR-T infusion) to keep the lymphoma or leukemia under control. Rapidly progressing disease that cannot be temporarily controlled may make the process unsafe or impractical.
6. Practical and social considerations
CAR-T requires a period of close monitoring, often including hospitalization and restricted contact after discharge because of infection risk. Centers therefore also consider:
- Ability to stay near the treatment center for a defined period
- Presence of a caregiver or support person
- Understanding of the risks and the follow-up plan
Important: Eligibility is never automatic
Meeting general criteria on paper does not guarantee that CAR-T will be offered. Every case is reviewed by a multidisciplinary team that weighs expected benefit against risks for that specific patient. Two people with the same diagnosis and similar treatment history can receive different recommendations based on fitness, disease tempo, and practical factors.
Who is usually not a candidate (at the present time)
- Patients whose disease is still responding well to standard first- or second-line therapy and who have other good options
- Patients with severe, uncontrolled medical problems that would make the side effects of CAR-T unacceptably dangerous
- Patients with active, uncontrolled infections
- Situations in which adequate T cells cannot be collected or manufacturing is not expected to succeed
- Patients who cannot commit to the required monitoring period (unless alternative arrangements are possible)
Specific exclusion criteria also depend on the product and the clinical protocol. Some products have restrictions related to central nervous system involvement; others are studying expanded indications.
How eligibility is assessed in practice
A typical pathway includes:
- Referral or self-request with complete medical documentation
- Review of pathology, prior treatments, recent imaging and laboratory results
- Clinical evaluation (history, examination, performance status)
- Organ function tests and infection screening
- Multidisciplinary discussion
- Discussion of risks, benefits, alternatives and logistics with the patient and family
In the current technology-transfer pathway connected to Biruni Cell Therapy, formal clinical evaluation and treatment are organized through Biruni University Hospital, which is the institution with established access to this manufacturing route. An educational second-opinion review can be a useful first step to understand whether a full formal evaluation is likely to be appropriate.
Key takeaway
The best candidates for current CD19 CAR-T therapies are generally patients with relapsed or refractory B-cell lymphoma (or selected leukemias) who have already received multiple prior treatments, who still have adequate organ function and performance status, and whose disease can be managed during the manufacturing window.
Because the decision is complex and highly individual, the only reliable way to know whether CAR-T is an option in a specific case is a structured medical review by an experienced team.